NCT02190266 Pathogenesis and Genetics of Disseminated or Refractory Coccidioidomycosis
| NCT ID | NCT02190266 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Condition | Coccidioidomycosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 400 participants |
| Start Date | 2014-09-02 |
| Primary Completion | 2029-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 400 participants in total. It began in 2014-09-02 with a primary completion date of 2029-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Background: \- Coccidioidomycosis is caused by a fungus that grows in the southwest United States and parts of Mexico and South America. This disease is caused by breathing dust containing the fungus. It can lead to serious lung and breathing problems. Rarely, the fungus can infect other body parts. This is called disseminated coccidioidomycosis (DCM). If the fungus stays in the lungs for more than 6 months, it is called refractory coccidioidomycosis (RCM). People with DCM or RCM may have difficulty fighting off infection because of immune system problems. Researchers want to study the immune systems of people with DCM or RCM, to learn more about the disease and the best ways to treat it. They also want to learn more about the types of people that get DCM or RCM and about the fungus that causes it. Objectives: \- To learn more about DCM and RCM, the fungus that causes these diseases, and the people who get them. Eligibility: \- People over age 2 with DCM or RCM. Design: * Participants will be screened with a review of their medical records. * At the initial visit, participants will have: * Medical history and physical exam * Blood and urine tests. Some blood may be used for genetic testing. The samples will not include participants names. Participants will be notified only if the tests show something urgent about their DCM/RCM. Researchers think this sort of problem will be rare. * Questionnaire about their DCM/RCM * Sputum (mucus) collection. They will spit into a cup. * Participants will have 1 follow-up visit per year. They will have blood tests. They may have other procedures to treat their DCM/RCM.
Eligibility Criteria
* INCLUSION CRITERIA: To be eligible for this study, potential participants must meet the following criteria: 1. Age \>= 2 years old. a. Enrollment of pediatric patients who are acutely ill or likely to become acutely ill will be deferred until a time when they are considered medically stable by the PI. 2. Have a positive Coccidioides antigen load or culture proven (a) refractory pulmonary coccidioidomycosis or (b) disseminated coccidioidomycosis. 1. Refractory pulmonary coccidioidomycosis must have occurred for at least 6 months and includes progressive pulmonary involvement without significant pulmonary cavitation. 2. Disseminated CM is coccidioidomycosis infection in one or more regions outside of the chest. 3. Agree to undergo genetic testing. 4. Allow their samples to be stored for future research. EXCLUSION CRITERIA: 1. HIV infection 2. Currently taking more than 20 mg/day of prednisone or undergoing active immunosuppressive therapy in the opinion of the investigator 3. Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer s ability to give informed consent.
Contact & Investigator
Steven M Holland, M.D.
PRINCIPAL INVESTIGATOR
National Institute of Allergy and Infectious Diseases (NIAID)
Frequently Asked Questions
Who can join the NCT02190266 clinical trial?
This trial is open to participants of all sexes, aged 2 Years or older, up to 100 Years, studying Coccidioidomycosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02190266 currently recruiting?
Yes, NCT02190266 is actively recruiting participants. Contact the research team at dawn.shaw2@nih.gov for enrollment information.
Where is the NCT02190266 trial being conducted?
This trial is being conducted at Bethesda, United States.
Who is sponsoring the NCT02190266 clinical trial?
NCT02190266 is sponsored by National Institute of Allergy and Infectious Diseases (NIAID). The principal investigator is Steven M Holland, M.D. at National Institute of Allergy and Infectious Diseases (NIAID). The trial plans to enroll 400 participants.